Is Amgen Stock Still Telling Investors The Same Thing?
For questions about this article or underlying research, email help@trefis.com.
Amgen (AMGN) stock returned 43.5% from May 15 to November 13, 2026, against 2.6% for the S&P 500. Over those six months, Amgen reported a string of good news for the medicines it calls its key growth drivers, including new trial results on August 31 showing that Repatha, its cholesterol drug, reduced the risk of death in high-risk adults without a prior heart attack or stroke. Yet in the six months before May 15, the shares slipped about 1%. Could you have seen that news coming while the price stood still?

Amgen Named Growth Drivers A Year Before May 2026
For much of it, yes. Amgen’s management pointed to these medicines during the company’s own earnings calls. Discussing the first quarter of fiscal 2025 on May 1, 2025, management said sales volume grew 14% on growing patient demand, adding that its key growth drivers were “all early in their life cycles.” On the November 4, 2025 call, management said volume growth had once again led the company’s progress.
Then Amgen had drug news to back up those statements. The FDA approved UPLIZNA on December 11, 2025, for adults with generalized myasthenia gravis. On March 28, 2026, Amgen said Repatha cut the risk of a first major cardiovascular event by 31% in high-risk patients without known significant plaque buildup in their arteries. Both developments were public well before May 15.
The filed financial results offered a less clear picture. Amgen reported an operating margin of 30.9% for the quarter ended March 31, 2026, up from 14.5% a year earlier, according to a May 1 filing. Revenue growth in that quarter slowed to 5.8%, however, down from 8.6% in the quarter ended December 31, 2025. A reader in early May saw a company saying the right things while its top line was not yet speeding up, and the signs read more clearly now than they did then.
Amgen’s Growth Drivers Now Bring In Most Product Sales
By the November 3, 2026 call, the four key growth drivers Amgen named in May 2025 had become a list of six. Product sales grew 8% from a year earlier in the third quarter of fiscal 2026, while management said its six key growth drivers grew 27%. Those six now make up more than 70% of product sales. Repatha sales rose 37% to $1.1 billion. UPLIZNA grew sales 191% to $451 million.
Amgen’s profit rose in the same quarter. Its reported operating margin reached 35.8% in that quarter, up from 26.4% a year earlier. Other large drugmakers rose too, with AbbVie returning 42.1%, Merck 34.4% and Johnson & Johnson 27.4% over the same six months, so the gain was not Amgen’s alone.
Are Amgen’s Growth Drivers Still Gaining Ground?
On the latest call, management said they were, the same message it gave on its 2025 calls. Repatha’s U.S. weekly prescriptions from patients new to the drug were up more than 60% from a year earlier. EVENITY sales grew 39% in the third quarter, after 38% growth the quarter before.
You pay a premium over the broader market to own Amgen today. The stock trades at 26.8 times its earnings over the past twelve months, compared with 21.9 for the S&P 500. Management also expects a meaningful rise in operating expenses in the fourth quarter, in line with its usual year-end spending.
When the company next reports, expected in February 2027, sales growth at Amgen’s six key growth drivers is the figure to watch.
Want Income To Go With Your Growth Stocks?
Growth stocks pay off mostly when you sell. Dividend stocks pay you along the way. The Trefis Income Solution owns 50 companies chosen to keep paying, each with at least 10 straight years of dividends, yielding about 3x the S&P 500.
Spot an error or want more like this? Tell us in 10 seconds.